JP2016528894A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016528894A5 JP2016528894A5 JP2016530062A JP2016530062A JP2016528894A5 JP 2016528894 A5 JP2016528894 A5 JP 2016528894A5 JP 2016530062 A JP2016530062 A JP 2016530062A JP 2016530062 A JP2016530062 A JP 2016530062A JP 2016528894 A5 JP2016528894 A5 JP 2016528894A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- stem cell
- enzyme
- guide rna
- target dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000130 stem cell Anatomy 0.000 claims 25
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 24
- 108090000790 Enzymes Proteins 0.000 claims 23
- 102000004190 Enzymes Human genes 0.000 claims 23
- 150000007523 nucleic acids Chemical class 0.000 claims 21
- 229920002391 Guide RNA Polymers 0.000 claims 18
- 108020005004 Guide RNA Proteins 0.000 claims 18
- 108020004707 nucleic acids Proteins 0.000 claims 16
- 239000002773 nucleotide Substances 0.000 claims 8
- 125000003729 nucleotide group Chemical group 0.000 claims 8
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 5
- 230000000295 complement Effects 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 4
- 229920000033 CRISPR Polymers 0.000 claims 2
- 108010082319 CRISPR-Associated Protein 9 Proteins 0.000 claims 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N Doxycycline Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims 2
- 229960003722 Doxycycline Drugs 0.000 claims 2
- 229920000460 Mitochondrial DNA Polymers 0.000 claims 2
- 108020005196 Mitochondrial DNA Proteins 0.000 claims 2
- 102000008579 Transposases Human genes 0.000 claims 2
- 108010020764 Transposases Proteins 0.000 claims 2
- 108020005202 Viral DNA Proteins 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 1
- 229920001272 Exogenous DNA Polymers 0.000 claims 1
- 108009000261 Non-homologous end joining Proteins 0.000 claims 1
- 210000004027 cells Anatomy 0.000 claims 1
- 238000002744 homologous recombination Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000006011 modification reaction Methods 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 230000001737 promoting Effects 0.000 claims 1
Claims (34)
- 標的DNAに相補的なガイドRNAと共局在複合体を形成し且つ部位特異的に前記標的DNAを切断するCas酵素、を含む幹細胞内で、前記標的DNAを改変する方法であって、前記方法は、
前記標的DNAに相補的であり前記Cas酵素を前記標的DNAまで誘導(guide)するガイドRNA、をコードする第1外来性核酸を、前記幹細胞に導入すること;ここで前記ガイドRNAおよび前記Cas酵素は前記標的DNAに対する共局在複合体のメンバーである、
ドナー核酸配列を前記幹細胞に導入すること、
を含み、
前記ガイドRNAおよび前記Cas酵素が前記標的DNAに共局在し、前記Cas酵素が前記標的DNAを切断し、前記ドナー核酸配列が前記標的DNAに挿入されて前記幹細胞内で改変DNAを産生する、前記方法。 - 前記Cas酵素がCas9である、請求項1に記載の方法。
- 前記ガイドRNAが10ヌクレオチド〜500ヌクレオチドである、請求項1に記載の方法。
- 前記ガイドRNAが20ヌクレオチド〜100ヌクレオチドである、請求項1に記載の方法。
- 前記ガイドRNAがtracrRNA−crRNA融合体である、請求項1に記載の方法。
- 前記標的DNAがゲノムDNA、ミトコンドリアDNA、ウイルスDNA、または外来性DNAである、請求項1に記載の方法。
- 前記ドナー核酸配列が相同組換えにより挿入される、請求項1に記載の方法。
- 前記ドナー核酸配列が非相同末端結合により挿入される、請求項1に記載の方法。
- 前記Cas酵素または前記ガイドRNAが、前記幹細胞によって発現される外来性核酸として前記幹細胞に導入される、請求項1に記載の方法。
- 複数のドナー核酸および複数のガイドRNAを導入して、前記幹細胞内で前記標的DNAに複数の改変を生じさせることをさらに含む、請求項1に記載の方法。
- 幹細胞内で改変DNAを作製した後に、前記Cas酵素をコードする核酸が、前記幹細胞のゲノムから除去される、請求項1に記載の方法。
- 前記ガイドRNAが、前記幹細胞の周囲の媒体から前記幹細胞内へと導入される、請求項1に記載の方法。
- 前記ガイドRNAが5’キャップ構造を含む、請求項12に記載の方法。
- 前記ガイドRNAがホスフェート基を欠く、請求項12に記載の方法。
- 前記ガイドRNAが前記幹細胞の周囲の媒体から連続的に供給される、請求項1に記載の方法。
- 前記幹細胞は、前記Cas酵素をコードする核酸を含み且つ酵素により除去可能なベクターまたはカセットを前記幹細胞のゲノムDNAに挿入することにより、遺伝的に改変されている、請求項1に記載の方法。
- 前記ベクターがPiggybacベクターである、請求項16に記載の方法。
- 前記Cas酵素をコードする核酸が、酵素を用いて除去される、請求項16に記載の方法。
- 前記Cas酵素をコードする核酸を含む前記酵素により除去可能なベクターまたはカセットは、酵素を用いて除去される、請求項16に記載の方法。
- 前記Cas酵素をコードする核酸を含む前記酵素により除去可能なベクターまたはカセットは、酵素を用いて挿入される、請求項16に記載の方法。
- 前記Cas酵素をコードする核酸を含む前記酵素により除去可能なベクターまたはカセットは、トランスポゼースを用いて除去される、請求項16に記載の方法。
- 前記Cas酵素をコードする核酸は誘導可能である、請求項16に記載の方法。
- 前記Cas酵素をコードする核酸は、ドキシサイクリン誘導性プロモータの影響下にある、請求項16に記載の方法。
- 前記Cas酵素をコードする核酸は、ドキシサイクリンを用いて誘導可能である、請求項16に記載の方法。
- 標的DNAに相補的なガイドRNAと共局在複合体を形成し且つ部位特異的に前記標的DNAを切断するCas酵素、をコードする第1外来性核酸を含む、幹細胞。
- 前記標的DNAに相補的であり前記Cas酵素を前記標的DNAまで誘導(guide)するガイドRNA、をコードする第2外来性核酸をさらに含み、前記ガイドRNAおよび前記Cas酵素が前記標的DNAに対する共局在複合体のメンバーである、請求項25に記載の幹細胞。
- ドナー核酸配列をコードする第3外来性核酸をさらに含む、請求項26に記載の幹細胞。
- 前記Cas酵素の発現を促進するための誘導性プロモーターをさらに含む請求項25に記載の幹細胞。
- 前記第1外来性核酸が前記幹細胞のゲノムDNAからトランスポゼースを使用して除去可能である、請求項25に記載の幹細胞。
- 前記Cas酵素がCas9である、請求項25に記載の幹細胞。
- 前記ガイドRNAが10ヌクレオチド〜500ヌクレオチドである、請求項25に記載の幹細胞。
- 前記ガイドRNAが20ヌクレオチド〜100ヌクレオチドである、請求項25に記載の幹細胞。
- 前記ガイドRNAがtracrRNA−crRNA融合体である、請求項25に記載の幹細胞。
- 前記標的DNAがゲノムDNA、ミトコンドリアDNA、ウイルスDNA、または外来性DNAである、請求項25に記載の幹細胞。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361858866P | 2013-07-26 | 2013-07-26 | |
US61/858,866 | 2013-07-26 | ||
PCT/US2014/048140 WO2015013583A2 (en) | 2013-07-26 | 2014-07-25 | Genome engineering |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020028641A Division JP6993063B2 (ja) | 2013-07-26 | 2020-02-21 | ゲノムエンジニアリング |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016528894A JP2016528894A (ja) | 2016-09-23 |
JP2016528894A5 true JP2016528894A5 (ja) | 2017-07-20 |
JP6739335B2 JP6739335B2 (ja) | 2020-08-12 |
Family
ID=52390824
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016530062A Active JP6739335B2 (ja) | 2013-07-26 | 2014-07-25 | ゲノムエンジニアリング |
JP2020028641A Active JP6993063B2 (ja) | 2013-07-26 | 2020-02-21 | ゲノムエンジニアリング |
JP2021198648A Active JP7419328B2 (ja) | 2013-07-26 | 2021-12-07 | ゲノムエンジニアリング |
JP2024002064A Pending JP2024029218A (ja) | 2013-07-26 | 2024-01-10 | ゲノムエンジニアリング |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020028641A Active JP6993063B2 (ja) | 2013-07-26 | 2020-02-21 | ゲノムエンジニアリング |
JP2021198648A Active JP7419328B2 (ja) | 2013-07-26 | 2021-12-07 | ゲノムエンジニアリング |
JP2024002064A Pending JP2024029218A (ja) | 2013-07-26 | 2024-01-10 | ゲノムエンジニアリング |
Country Status (14)
Country | Link |
---|---|
US (4) | US10563225B2 (ja) |
EP (4) | EP3024964B1 (ja) |
JP (4) | JP6739335B2 (ja) |
KR (2) | KR20230096134A (ja) |
CN (3) | CN105473773B (ja) |
AU (4) | AU2014293015B2 (ja) |
BR (1) | BR112016001721B1 (ja) |
CA (1) | CA2918540A1 (ja) |
ES (1) | ES2715666T3 (ja) |
HK (1) | HK1218940A1 (ja) |
IL (2) | IL243560B (ja) |
RU (2) | RU2688462C2 (ja) |
SG (3) | SG11201600217QA (ja) |
WO (1) | WO2015013583A2 (ja) |
Families Citing this family (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
SG11201406547YA (en) | 2012-04-25 | 2014-11-27 | Regeneron Pharma | Nuclease-mediated targeting with large targeting vectors |
IL308158A (en) | 2012-12-17 | 2023-12-01 | Harvard College | RNA-guided human genome engineering |
EP2981617B1 (en) | 2013-04-04 | 2023-07-05 | President and Fellows of Harvard College | Therapeutic uses of genome editing with crispr/cas systems |
DK2986729T3 (en) | 2013-04-16 | 2018-10-29 | Regeneron Pharma | TARGETED MODIFICATION OF ROOT THROUGH |
JP2016528890A (ja) | 2013-07-09 | 2016-09-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | CRISPR/Cas系を用いるゲノム編集の治療用の使用 |
US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
DE202014010413U1 (de) | 2013-09-18 | 2015-12-08 | Kymab Limited | Zellen und Organismen |
WO2015070083A1 (en) | 2013-11-07 | 2015-05-14 | Editas Medicine,Inc. | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS |
RU2685914C1 (ru) | 2013-12-11 | 2019-04-23 | Регенерон Фармасьютикалс, Инк. | Способы и композиции для направленной модификации генома |
US9840699B2 (en) | 2013-12-12 | 2017-12-12 | President And Fellows Of Harvard College | Methods for nucleic acid editing |
EP3690044B1 (en) | 2014-02-11 | 2024-01-10 | The Regents of the University of Colorado, a body corporate | Crispr enabled multiplexed genome engineering |
EP3114227B1 (en) | 2014-03-05 | 2021-07-21 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa |
US11339437B2 (en) | 2014-03-10 | 2022-05-24 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
WO2015138510A1 (en) | 2014-03-10 | 2015-09-17 | Editas Medicine., Inc. | Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10) |
US11141493B2 (en) | 2014-03-10 | 2021-10-12 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
WO2015148863A2 (en) | 2014-03-26 | 2015-10-01 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating sickle cell disease |
WO2015191693A2 (en) * | 2014-06-10 | 2015-12-17 | Massachusetts Institute Of Technology | Method for gene editing |
EP3177718B1 (en) | 2014-07-30 | 2022-03-16 | President and Fellows of Harvard College | Cas9 proteins including ligand-dependent inteins |
MX2017004890A (es) | 2014-10-15 | 2018-02-12 | Regeneron Pharma | Metodos y composiciones para la generación o el mantenimiento de células pluripotentes. |
WO2016065364A1 (en) * | 2014-10-24 | 2016-04-28 | Life Technologies Corporation | Compositions and methods for enhancing homologous recombination |
WO2016073990A2 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
NZ731962A (en) | 2014-11-21 | 2022-07-01 | Regeneron Pharma | Methods and compositions for targeted genetic modification using paired guide rnas |
CN107250148B (zh) | 2014-12-03 | 2021-04-16 | 安捷伦科技有限公司 | 具有化学修饰的指导rna |
WO2016094679A1 (en) | 2014-12-10 | 2016-06-16 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
EP3271461A1 (en) * | 2015-03-20 | 2018-01-24 | Danmarks Tekniske Universitet | Crispr/cas9 based engineering of actinomycetal genomes |
EP4019635A1 (en) * | 2015-03-25 | 2022-06-29 | Editas Medicine, Inc. | Crispr/cas-related methods, compositions and components |
KR102648489B1 (ko) | 2015-04-06 | 2024-03-15 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna |
SG11201708653RA (en) | 2015-04-24 | 2017-11-29 | Editas Medicine Inc | Evaluation of cas9 molecule/guide rna molecule complexes |
JP7030522B2 (ja) * | 2015-05-11 | 2022-03-07 | エディタス・メディシン、インコーポレイテッド | 幹細胞における遺伝子編集のための最適化crispr/cas9システムおよび方法 |
WO2016196887A1 (en) | 2015-06-03 | 2016-12-08 | Board Of Regents Of The University Of Nebraska | Dna editing using single-stranded dna |
CN116334142A (zh) | 2015-06-09 | 2023-06-27 | 爱迪塔斯医药公司 | 用于改善移植的crispr/cas相关方法和组合物 |
US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
WO2016205749A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
CN109536474A (zh) | 2015-06-18 | 2019-03-29 | 布罗德研究所有限公司 | 降低脱靶效应的crispr酶突变 |
US10166255B2 (en) | 2015-07-31 | 2019-01-01 | Regents Of The University Of Minnesota | Intracellular genomic transplant and methods of therapy |
WO2017040511A1 (en) | 2015-08-31 | 2017-03-09 | Agilent Technologies, Inc. | Compounds and methods for crispr/cas-based genome editing by homologous recombination |
US11667911B2 (en) | 2015-09-24 | 2023-06-06 | Editas Medicine, Inc. | Use of exonucleases to improve CRISPR/CAS-mediated genome editing |
EP3365356B1 (en) | 2015-10-23 | 2023-06-28 | President and Fellows of Harvard College | Nucleobase editors and uses thereof |
ES2953925T3 (es) * | 2015-11-04 | 2023-11-17 | Fate Therapeutics Inc | Ingeniería genómica de células pluripotentes |
KR101885901B1 (ko) * | 2015-11-13 | 2018-08-07 | 기초과학연구원 | 5' 말단의 인산기가 제거된 rna를 포함하는 리보핵산단백질 전달용 조성물 |
WO2017087708A1 (en) | 2015-11-19 | 2017-05-26 | The Brigham And Women's Hospital, Inc. | Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity |
EP3383409A4 (en) * | 2015-12-02 | 2019-10-02 | The Regents of The University of California | COMPOSITIONS AND METHODS FOR MODIFYING TARGET NUCLEIC ACID |
US11441146B2 (en) * | 2016-01-11 | 2022-09-13 | Christiana Care Health Services, Inc. | Compositions and methods for improving homogeneity of DNA generated using a CRISPR/Cas9 cleavage system |
CN106957856B (zh) * | 2016-01-12 | 2020-07-28 | 中国科学院广州生物医药与健康研究院 | 无毛模型猪的重构卵及其构建方法和模型猪的构建方法 |
WO2017165862A1 (en) | 2016-03-25 | 2017-09-28 | Editas Medicine, Inc. | Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency |
US11597924B2 (en) | 2016-03-25 | 2023-03-07 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
WO2017180694A1 (en) | 2016-04-13 | 2017-10-19 | Editas Medicine, Inc. | Cas9 fusion molecules gene editing systems, and methods of use thereof |
CA3026112A1 (en) | 2016-04-19 | 2017-10-26 | The Broad Institute, Inc. | Cpf1 complexes with reduced indel activity |
WO2017184768A1 (en) | 2016-04-19 | 2017-10-26 | The Broad Institute Inc. | Novel crispr enzymes and systems |
KR20230038804A (ko) * | 2016-04-29 | 2023-03-21 | 바스프 플랜트 사이언스 컴퍼니 게엠베하 | 표적 핵산의 변형을 위한 개선된 방법 |
WO2017207589A1 (en) * | 2016-06-01 | 2017-12-07 | Kws Saat Se | Hybrid nucleic acid sequences for genome engineering |
US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
WO2017223538A1 (en) | 2016-06-24 | 2017-12-28 | The Regents Of The University Of Colorado, A Body Corporate | Methods for generating barcoded combinatorial libraries |
US11471462B2 (en) | 2016-06-27 | 2022-10-18 | The Broad Institute, Inc. | Compositions and methods for detecting and treating diabetes |
US11359234B2 (en) | 2016-07-01 | 2022-06-14 | Microsoft Technology Licensing, Llc | Barcoding sequences for identification of gene expression |
US20180004537A1 (en) * | 2016-07-01 | 2018-01-04 | Microsoft Technology Licensing, Llc | Molecular State Machines |
US11566263B2 (en) | 2016-08-02 | 2023-01-31 | Editas Medicine, Inc. | Compositions and methods for treating CEP290 associated disease |
GB2568182A (en) | 2016-08-03 | 2019-05-08 | Harvard College | Adenosine nucleobase editors and uses thereof |
AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
EP3510151A4 (en) | 2016-09-09 | 2020-04-15 | The Board of Trustees of the Leland Stanford Junior University | HIGH-THROUGHPUT PRECISION GENE EDITING |
KR102622411B1 (ko) | 2016-10-14 | 2024-01-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
CN110520530A (zh) | 2016-10-18 | 2019-11-29 | 明尼苏达大学董事会 | 肿瘤浸润性淋巴细胞和治疗方法 |
KR20190089175A (ko) * | 2016-11-18 | 2019-07-30 | 진에딧 인코포레이티드 | 표적 핵산 변형을 위한 조성물 및 방법 |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
US11530388B2 (en) * | 2017-02-14 | 2022-12-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of engineering human induced pluripotent stem cells to produce liver tissue |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
WO2018165629A1 (en) | 2017-03-10 | 2018-09-13 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
EP3596217A1 (en) | 2017-03-14 | 2020-01-22 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
EP3601562A1 (en) | 2017-03-23 | 2020-02-05 | President and Fellows of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
US20210115407A1 (en) | 2017-04-12 | 2021-04-22 | The Broad Institute, Inc. | Respiratory and sweat gland ionocytes |
WO2018195486A1 (en) | 2017-04-21 | 2018-10-25 | The Broad Institute, Inc. | Targeted delivery to beta cells |
EP3615672A1 (en) | 2017-04-28 | 2020-03-04 | Editas Medicine, Inc. | Methods and systems for analyzing guide rna molecules |
WO2018204777A2 (en) | 2017-05-05 | 2018-11-08 | The Broad Institute, Inc. | Methods for identification and modification of lncrna associated with target genotypes and phenotypes |
EP3622070A2 (en) | 2017-05-10 | 2020-03-18 | Editas Medicine, Inc. | Crispr/rna-guided nuclease systems and methods |
WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
AU2018279829B2 (en) | 2017-06-09 | 2024-01-04 | Editas Medicine, Inc. | Engineered Cas9 nucleases |
US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
US10011849B1 (en) | 2017-06-23 | 2018-07-03 | Inscripta, Inc. | Nucleic acid-guided nucleases |
WO2019006418A2 (en) | 2017-06-30 | 2019-01-03 | Intima Bioscience, Inc. | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY |
WO2019014564A1 (en) | 2017-07-14 | 2019-01-17 | Editas Medicine, Inc. | SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
MX2020001178A (es) | 2017-07-31 | 2020-09-25 | Regeneron Pharma | Celulas madre embrionarias de raton transgenico con cas y ratones y usos de los mismos. |
EP3676376A2 (en) | 2017-08-30 | 2020-07-08 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
CN111344403A (zh) * | 2017-09-15 | 2020-06-26 | 利兰斯坦福初级大学董事会 | 遗传工程细胞的多元性产生和条形码编制 |
KR20200121782A (ko) | 2017-10-16 | 2020-10-26 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
US11268092B2 (en) | 2018-01-12 | 2022-03-08 | GenEdit, Inc. | Structure-engineered guide RNA |
CN112272516B (zh) | 2018-04-06 | 2023-05-30 | 儿童医疗中心有限公司 | 用于体细胞重新编程和调整印记的组合物和方法 |
GB2589246A (en) | 2018-05-16 | 2021-05-26 | Synthego Corp | Methods and systems for guide RNA design and use |
US20210246505A1 (en) * | 2018-06-21 | 2021-08-12 | Memorial Sloan Kettering Cancer Center | Compositions & methods for monitoring dna repair |
KR20210053898A (ko) | 2018-07-31 | 2021-05-12 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신규 crispr 효소 및 시스템 |
CA3121268A1 (en) | 2018-12-10 | 2020-06-18 | Amgen Inc. | Mutated piggybac transposase |
BR112021018606A2 (pt) | 2019-03-19 | 2021-11-23 | Harvard College | Métodos e composições para editar sequências de nucleotídeos |
CN115175996A (zh) | 2019-09-20 | 2022-10-11 | 博德研究所 | 新颖vi型crispr酶和系统 |
EP4146797A1 (en) | 2020-05-06 | 2023-03-15 | Orchard Therapeutics (Europe) Limited | Treatment for neurodegenerative diseases |
DE112021002672T5 (de) | 2020-05-08 | 2023-04-13 | President And Fellows Of Harvard College | Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz |
EP4232583A1 (en) | 2020-10-21 | 2023-08-30 | Massachusetts Institute of Technology | Systems, methods, and compositions for site-specific genetic engineering using programmable addition via site-specific targeting elements (paste) |
TW202233660A (zh) | 2020-10-30 | 2022-09-01 | 美商安進公司 | 過表現胰島素樣生長因子受體突變體以調節igf補充 |
KR20240055811A (ko) | 2021-09-10 | 2024-04-29 | 애질런트 테크놀로지스, 인크. | 프라임 편집을 위한 화학적 변형을 갖는 가이드 rna |
CA3237300A1 (en) | 2021-11-01 | 2023-05-04 | Tome Biosciences, Inc. | Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo |
WO2023122764A1 (en) | 2021-12-22 | 2023-06-29 | Tome Biosciences, Inc. | Co-delivery of a gene editor construct and a donor template |
WO2023205744A1 (en) | 2022-04-20 | 2023-10-26 | Tome Biosciences, Inc. | Programmable gene insertion compositions |
WO2023225670A2 (en) | 2022-05-20 | 2023-11-23 | Tome Biosciences, Inc. | Ex vivo programmable gene insertion |
WO2024020587A2 (en) | 2022-07-22 | 2024-01-25 | Tome Biosciences, Inc. | Pleiopluripotent stem cell programmable gene insertion |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5641670A (en) * | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US6689558B2 (en) | 2000-02-08 | 2004-02-10 | Sangamo Biosciences, Inc. | Cells for drug discovery |
EP1280928B1 (en) * | 2000-05-10 | 2016-11-30 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Resistance to acetohydroxyacid synthase-inhibiting herbicides |
CA2474486C (en) | 2002-01-23 | 2013-05-14 | The University Of Utah Research Foundation | Targeted chromosomal mutagenesis using zinc finger nucleases |
KR100766952B1 (ko) | 2002-12-09 | 2007-10-17 | 주식회사 툴젠 | 조절성 징크 핑거 단백질 |
JP2007521823A (ja) | 2004-02-13 | 2007-08-09 | ノボザイムス アクティーゼルスカブ | プロテアーゼ変異型 |
DE102005062662A1 (de) | 2005-12-23 | 2007-06-28 | Basf Ag | Verfahren zur Herstellung optisch aktiver Alkohole |
BRPI0808704B1 (pt) | 2007-03-02 | 2022-01-18 | Dupont Nutrition Biosciences Aps | Método para gerar uma cultura inicial compreendendo pelo menos duas cepas variantes resistentes a bacteriófagos, cultura iniciadora e método de fermentação |
US8546553B2 (en) | 2008-07-25 | 2013-10-01 | University Of Georgia Research Foundation, Inc. | Prokaryotic RNAi-like system and methods of use |
US20100076057A1 (en) | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
US9404098B2 (en) | 2008-11-06 | 2016-08-02 | University Of Georgia Research Foundation, Inc. | Method for cleaving a target RNA using a Cas6 polypeptide |
PH12012500097A1 (en) * | 2009-07-21 | 2011-01-27 | Shanghai Inst Organic Chem | Potent small molecule inhibitors of autophagy, and methods of use thereof |
PT2816112T (pt) | 2009-12-10 | 2018-11-20 | Univ Iowa State Res Found Inc | Modificação do adn modificada pelo efector tal |
NO332016B1 (no) | 2009-12-29 | 2012-05-21 | Stiftelsen Sintef | Prøvebehandlingskassett og fremgangsmåte for å behandle og/eller analysere en prøve under sentrifugalkraft |
GB201000591D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
MX336731B (es) * | 2010-01-28 | 2016-01-28 | Harvard College | Composiciones y metodos para potenciar la actividad de proteasoma. |
US10087431B2 (en) | 2010-03-10 | 2018-10-02 | The Regents Of The University Of California | Methods of generating nucleic acid fragments |
BR112012028805A2 (pt) | 2010-05-10 | 2019-09-24 | The Regents Of The Univ Of California E Nereus Pharmaceuticals Inc | composições de endorribonuclease e métodos de uso das mesmas. |
CN103025344B (zh) | 2010-05-17 | 2016-06-29 | 桑格摩生物科学股份有限公司 | 新型dna-结合蛋白及其用途 |
US20140113376A1 (en) | 2011-06-01 | 2014-04-24 | Rotem Sorek | Compositions and methods for downregulating prokaryotic genes |
CA2841541C (en) | 2011-07-25 | 2019-11-12 | Sangamo Biosciences, Inc. | Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene |
US8450107B1 (en) | 2011-11-30 | 2013-05-28 | The Broad Institute Inc. | Nucleotide-specific recognition sequences for designer TAL effectors |
GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
RU2650811C2 (ru) | 2012-02-24 | 2018-04-17 | Фред Хатчинсон Кэнсер Рисерч Сентер | Композиции и способы лечения гемоглобинопатии |
EP2820159B1 (en) | 2012-02-29 | 2019-10-23 | Sangamo Therapeutics, Inc. | Methods and compositions for treating huntington's disease |
WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
ES2960803T3 (es) | 2012-05-25 | 2024-03-06 | Univ California | Métodos y composiciones para la modificación de ADN diana dirigida por RNA y para la modulación de la transcripción dirigida por RNA |
EP2880171B1 (en) | 2012-08-03 | 2018-10-03 | The Regents of The University of California | Methods and compositions for controlling gene expression by rna processing |
ES2926021T3 (es) | 2012-10-23 | 2022-10-21 | Toolgen Inc | Composición para escindir un ADN objetivo que comprende un ARN guía específico para el ADN objetivo y ácido nucleico codificador de proteína Cas o proteína Cas, y uso de la misma |
EP3617309A3 (en) | 2012-12-06 | 2020-05-06 | Sigma Aldrich Co. LLC | Crispr-based genome modification and regulation |
SG10201912328UA (en) | 2012-12-12 | 2020-02-27 | Broad Inst Inc | Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications |
CN113355357A (zh) | 2012-12-12 | 2021-09-07 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
AU2014235794A1 (en) | 2013-03-14 | 2015-10-22 | Caribou Biosciences, Inc. | Compositions and methods of nucleic acid-targeting nucleic acids |
US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
US20140349400A1 (en) | 2013-03-15 | 2014-11-27 | Massachusetts Institute Of Technology | Programmable Modification of DNA |
EP2981617B1 (en) | 2013-04-04 | 2023-07-05 | President and Fellows of Harvard College | Therapeutic uses of genome editing with crispr/cas systems |
US20140349405A1 (en) | 2013-05-22 | 2014-11-27 | Wisconsin Alumni Research Foundation | Rna-directed dna cleavage and gene editing by cas9 enzyme from neisseria meningitidis |
US11685935B2 (en) | 2013-05-29 | 2023-06-27 | Cellectis | Compact scaffold of Cas9 in the type II CRISPR system |
WO2014198911A1 (en) | 2013-06-14 | 2014-12-18 | Cellectis | Improved polynucleotide sequences encoding tale repeats |
WO2014204725A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation |
CA2933134A1 (en) | 2013-12-13 | 2015-06-18 | Cellectis | Cas9 nuclease platform for microalgae genome engineering |
-
2014
- 2014-06-30 US US14/319,380 patent/US10563225B2/en active Active
- 2014-06-30 US US14/319,498 patent/US11306328B2/en active Active
- 2014-07-25 SG SG11201600217QA patent/SG11201600217QA/en unknown
- 2014-07-25 SG SG10201800259WA patent/SG10201800259WA/en unknown
- 2014-07-25 EP EP14829377.2A patent/EP3024964B1/en active Active
- 2014-07-25 CN CN201480042306.1A patent/CN105473773B/zh active Active
- 2014-07-25 EP EP21176056.6A patent/EP3916099B1/en active Active
- 2014-07-25 WO PCT/US2014/048140 patent/WO2015013583A2/en active Application Filing
- 2014-07-25 AU AU2014293015A patent/AU2014293015B2/en active Active
- 2014-07-25 KR KR1020237020511A patent/KR20230096134A/ko not_active Application Discontinuation
- 2014-07-25 RU RU2016106649A patent/RU2688462C2/ru active
- 2014-07-25 CN CN202010094041.7A patent/CN111304230A/zh active Pending
- 2014-07-25 KR KR1020167004663A patent/KR20160035017A/ko not_active IP Right Cessation
- 2014-07-25 EP EP18212761.3A patent/EP3483277B1/en active Active
- 2014-07-25 EP EP23164284.4A patent/EP4234703A3/en active Pending
- 2014-07-25 RU RU2019114217A patent/RU2764757C2/ru active
- 2014-07-25 SG SG10201913000PA patent/SG10201913000PA/en unknown
- 2014-07-25 ES ES14829377T patent/ES2715666T3/es active Active
- 2014-07-25 US US14/907,605 patent/US9914939B2/en active Active
- 2014-07-25 JP JP2016530062A patent/JP6739335B2/ja active Active
- 2014-07-25 CA CA2918540A patent/CA2918540A1/en active Pending
- 2014-07-25 BR BR112016001721-8A patent/BR112016001721B1/pt active IP Right Grant
- 2014-07-25 CN CN202410183863.0A patent/CN118028379A/zh active Pending
-
2016
- 2016-01-11 IL IL243560A patent/IL243560B/en active IP Right Grant
- 2016-06-14 HK HK16106842.9A patent/HK1218940A1/zh unknown
-
2018
- 2018-12-12 AU AU2018278911A patent/AU2018278911C1/en active Active
-
2020
- 2020-01-22 IL IL272193A patent/IL272193B/en unknown
- 2020-02-21 JP JP2020028641A patent/JP6993063B2/ja active Active
-
2021
- 2021-04-27 AU AU2021202581A patent/AU2021202581B2/en active Active
- 2021-12-07 JP JP2021198648A patent/JP7419328B2/ja active Active
-
2022
- 2022-04-07 US US17/715,177 patent/US20220235382A1/en active Pending
-
2023
- 2023-10-13 AU AU2023248167A patent/AU2023248167A1/en active Pending
-
2024
- 2024-01-10 JP JP2024002064A patent/JP2024029218A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016528894A5 (ja) | ||
RU2019114217A (ru) | Геномная инженерия | |
RU2016104056A (ru) | Мультиплексная геномная инженерия, направляемая рнк | |
Song et al. | Efficient genome editing using tRNA promoter-driven CRISPR/Cas9 gRNA in Aspergillus niger | |
Shi et al. | CRISPR/Cas9-based genome editing of the filamentous fungi: the state of the art | |
Tröder et al. | An optimized electroporation approach for efficient CRISPR/Cas9 genome editing in murine zygotes | |
Chen et al. | Highly efficient mouse genome editing by CRISPR ribonucleoprotein electroporation of zygotes | |
EA201991441A1 (ru) | ТЕРМОСТАБИЛЬНЫЕ НУКЛЕАЗЫ Cas9 | |
Niu et al. | Transformation of diatom Phaeodactylum tricornutum by electroporation and establishment of inducible selection marker | |
JP2018508198A5 (ja) | ||
MX2018013256A (es) | Metodos mejorados para la modificacion de acido nucleicos diana. | |
MX2019012772A (es) | Metodos y composiciones para la modificacion de adn objetivo dirigida por arn y para la modulacion de la transcripcion dirigida por arn. | |
JP2016027807A5 (ja) | ||
JP2019508051A5 (ja) | ||
EP4170029A3 (en) | Modifying the specifity of plant non-coding rna molecules for silencing gene expression | |
JP2016537982A5 (ja) | ||
RU2015129018A (ru) | Рнк-направляемая инженерия генома человека | |
JP2016502840A5 (ja) | ||
MX2016007654A (es) | Metodos y composiciones para la modificacion dirigida de un genoma. | |
JP2010500029A5 (ja) | ||
JP2012130346A5 (ja) | ||
JP2016512691A5 (ja) | ||
RU2014127702A (ru) | Модифицированные Cascade-рибонуклеопротеины и их применения | |
WO2014039692A3 (en) | Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks | |
BR112012014080A2 (pt) | método para modificação do material genético, método para geração de um ácido nucleico, monômero de endonuclease efetora tal, método para geração de um aninal, método para geração de uma planta, método para recombinação genética direcionada, ácido nucleico, cassete de expressão e célula hospedeira |